Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLID: Yttrium-90 radioembolization plus durvalumab in unresectable hepatocellular carcinoma
KCT0004221Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Started Jun 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0004221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004221.